Baxter uses cell separation technology, enters stem cell field

04/18/2007 | Reuters

Best known for IV drips, Baxter International, has quietly entered the $1 billion potential market of stem cell research with a trial making use of its cell separation technology. The trial uses autologous stem cell therapy, which involves harvesting stem cells from the patient's own bone marrow, to repair oxygen-deprived heart tissue. The drug G-CSF is administered to stimulate the bone marrow to produce more stem cells.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID